Novel 2,4-Pyrimidinediamine Derivative as Potent EGFR Inhibitor for NSCLC Treatment. (PubMed, Molecules) - Oct 17, 2026 - "Compared to its lead compound ceritinib, which has weak cytotoxicity for EGFR-driven NSCLC, ZX-3 exhibited potent cytotoxicity against EGFR-driven NSCLC...In in vivo xenograft studies, ZX-3 treatment significantly suppressed tumor growth without obvious toxicity. Collectively, ZX-3 represents a reversible EGFR inhibitor based on borylation modification and possesses favorable antitumor activity both in vitro and in vivo, offering a novel strategy for the subsequent development of EGFR-targeted inhibitors."
Journal • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor
|
|
Jia Lv; Shiqi Jia; Xiaolin Lv; Yiran Wu
|